Summary

Egypt In-Vitro Diagnostics Market Research Report Information by Product & Service (Reagents & Kits, Instruments, and Software and Services), by Technology (Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, and Others), by Application (Infectious Diseases, Immunology, Oncology, Cardiology, Diabetes, HIV/AIDS, and Others), by End User (Hospitals, Laboratories, Point-of-Care Testing, Research and Academic Institutions, and Others) Forecast to 2032

Market Overview

Egypt the In-Vitro Diagnostics Market is expected to grow at a robust CAGR of 7.49% during the research period. In-vitro Diagnostic (IVD) refers to medical testing and diagnostic procedures that use blood, urine, tissues, or other bodily fluids collected from a patient's body. These tests are performed outside of the patient's body, usually in a laboratory setting, to detect diseases, infections, disorders, or other medical information. IVD plays an important role in offering vital insights into a patient's health status, assisting in the diagnosis, prognosis, and monitoring of numerous diseases and medical conditions.
The increasing occurrences and prevalence of numerous diseases in Egypt, as well as a growing emphasis on early detection and preventative care, are the primary drivers of the Egypt In-Vitro Diagnostics Market. However, advances in IVD technology, such as the development of more precise, quick, and user-friendly diagnostic tools, are projected to impede worldwide market growth. Nonetheless, the construction and expansion of diagnostic laboratories in Egypt and around the world is expected to provide profitable prospects for the industry.

Marketing Segmentation
The Egypt In-vitro Diagnostic market is divided into three segments based on product and service: reagents and kits, instruments, and software and services.
Based on technology, the Egypt In-vitro Diagnostic market is divided into Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, and Other. The immunoassay/immunochemistry category dominated the market in 2023, while clinical chemistry is expected to be the fastest-growing segment during the forecast period (2024-2032).
According on application, the Egypt In-vitro Diagnostic market is divided into Infectious Diseases, Immunology, Oncology, Cardiology, Diabetes, HIV/AIDS, and Others.
The market is divided into five segments based on end users: hospitals, laboratories, point-of-care testing, research and academic institutions, and others.
Major Players
F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott, Thermo Fisher Scientific Inc., Sysmex Corporation, Danaher Corporation, Bio-Rad Laboratories, Inc., and DiaSorin S.p.A. are the leading companies in Egypt's in-vitro diagnostic industry.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
EXECUTIVE SUMMARY 13
1 MARKET INTRODUCTION 15
1.1 DEFINITION 15
1.2 SCOPE OF THE STUDY 15
1.3 RESEARCH OBJECTIVE 15
1.4 MARKET STRUCTURE 16
2 RESEARCH METHODOLOGY 17
2.1 OVERVIEW 17
2.2 DATA FLOW 19
2.2.1 DATA MINING PROCESS 19
2.3 PURCHASED DATABASE: 20
2.4 SECONDARY SOURCES: 21
2.4.1 SECONDARY RESEARCH DATA FLOW: 22
2.5 PRIMARY RESEARCH: 23
2.5.1 PRIMARY RESEARCH DATA FLOW: 24
2.6 APPROACHES FOR MARKET SIZE ESTIMATION: 25
2.6.1 REVENUE ANALYSIS APPROACH 25
2.7 DATA FORECASTING 26
2.7.1 DATA FORECASTING TYPE 26
2.8 DATA MODELING 27
2.8.1 MICROECONOMIC FACTOR ANALYSIS: 27
2.8.2 DATA MODELING: 28
2.9 TEAMS AND ANALYST CONTRIBUTION 30
3 MARKET DYNAMICS 32
3.1 INTRODUCTION 32
3.2 DRIVERS 33
3.2.1 INCREASING INCIDENCES AND PREVELANCES OF VARIOUS DISEASES ACROSS EGYPT 33
3.2.2 GROWING FOCUS ON EARLY DIAGNOSIS AND PREVENTIVE CARE 33
3.3 RESTRAINTS 34
3.3.1 CONCERNS REGARDING THE ACCURACY AND PRECISION OF IN-VITRO DIAGNOSTICS (IVD) 34
3.4 OPPORTUNITY 35
3.4.1 EXPANSION OF MANUFACTURING FACILITIES IN EGYPT 35
4 MARKET FACTOR ANALYSIS 37
4.1 PORTER'S FIVE FORCES MODEL 37
4.1.1 THREAT OF NEW ENTRANTS 37
4.1.2 BARGAINING POWER OF SUPPLIERS 38
4.1.3 THREAT OF SUBSTITUTES 38
4.1.4 BARGAINING POWER OF BUYERS 38
4.1.5 INTENSITY OF RIVALRY 38
4.2 IMPACT OF COVID-19 ON THE EGYPT IN-VITRO DIAGNOSTICS MARKET 39
5 EGYPT IN-VITRO DIAGNOSTIC MARKET, BY PRODUCT & SERVICE 41
5.1 OVERVIEW 41
6 EGYPT IN-VITRO DIAGNOSTIC MARKET, BY TECHNOLOGY 43
6.1 OVERVIEW 43
7 EGYPT IN-VITRO DIAGNOSTIC MARKET, BY APPLICATION 46
7.1 OVERVIEW 46
8 EGYPT IN-VITRO DIAGNOSTIC MARKET, BY END USER 49
8.1 OVERVIEW 49
9 COMPETITIVE LANDSCAPE 52
9.1 INTRODUCTION 52
9.2 MARKET SHARE ANALYSIS, 2023 52
9.3 COMPETITOR DASHBOARD 53
9.4 PUBLIC PLAYERS STOCK SUMMARY 54
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 54
10 COMPANY PROFILES 55
10.1 F. HOFFMANN-LA ROCHE LTD. 55
10.1.1 COMPANY OVERVIEW 55
10.1.2 FINANCIAL OVERVIEW 56
10.1.3 PRODUCTS OFFERED 56
10.1.4 KEY DEVELOPMENTS 58
10.1.5 SWOT ANALYSIS 59
10.1.6 KEY STRATEGIES 59
10.2 ABBOTT 60
10.2.1 COMPANY OVERVIEW 60
10.2.2 FINANCIAL OVERVIEW 61
10.2.3 PRODUCTS OFFERED 61
10.2.4 KEY DEVELOPMENTS 62
10.2.5 SWOT ANALYSIS 63
10.2.6 KEY STRATEGIES 63
10.3 SIEMENS HEALTHINEERS 64
10.3.1 COMPANY OVERVIEW 64
10.3.2 FINANCIAL OVERVIEW 65
10.3.3 PRODUCTS OFFERED 66
10.3.4 KEY DEVELOPMENTS 67
10.3.5 SWOT ANALYSIS 67
10.3.6 KEY STRATEGIES 68
10.4 THERMO FISHER SCIENTIFIC INC. 69
10.4.1 COMPANY OVERVIEW 69
10.4.2 FINANCIAL OVERVIEW 70
10.4.3 PRODUCTS OFFERED 70
10.4.4 KEY DEVELOPMENTS 71
10.4.5 SWOT ANALYSIS 72
10.4.6 KEY STRATEGIES 72
10.5 SYSMEX CORPORATION 73
10.5.1 COMPANY OVERVIEW 73
10.5.2 FINANCIAL OVERVIEW 73
10.5.3 PRODUCTS OFFERED 74
10.5.4 KEY DEVELOPMENTS 76
10.5.5 KEY STRATEGIES 76
10.6 SPECTRUM DIAGNOSTICS 77
10.6.1 COMPANY OVERVIEW 77
10.6.2 FINANCIAL OVERVIEW 77
10.6.3 PRODUCTS OFFERED 77
10.6.4 KEY DEVELOPMENTS 79
10.6.5 KEY STRATEGIES 79
10.7 DANAHER CORPORATION 81
10.7.1 COMPANY OVERVIEW 81
10.7.2 FINANCIAL OVERVIEW 82
10.7.3 PRODUCTS OFFERED 82
10.7.4 KEY DEVELOPMENTS 83
10.7.5 KEY STRATEGIES 83
10.8 DIASORIN S.P.A. 84
10.8.1 COMPANY OVERVIEW 84
10.8.2 FINANCIAL OVERVIEW 85
10.8.3 PRODUCTS OFFERED 86
10.8.4 KEY DEVELOPMENTS 86
10.8.5 KEY STRATEGIES 87
10.9 BIO-RAD LABORATORIES, INC. 88
10.9.1 COMPANY OVERVIEW 88
10.9.2 FINANCIAL OVERVIEW 89
10.9.3 PRODUCTS OFFERED 89
10.9.4 KEY DEVELOPMENTS 91
10.9.5 SWOT ANALYSIS 92
10.9.6 KEY STRATEGIES 92
10.10 RANDOX LABORATORIES LTD. 93
10.10.1 COMPANY OVERVIEW 93
10.10.2 FINANCIAL OVERVIEW 93
10.10.3 PRODUCTS OFFERED 94
10.10.4 KEY DEVELOPMENTS 94
10.10.5 KEY STRATEGIES 95
11 DATA CITATIONS 96